Steatohepatitis/Metabolic Liver Disease News

Vupanorsen, an investigational antisense therapy, reduced triglyceride levels at 6 months and demonstrated benefit on additional lipid parameters compared with placebo in patients with hypertriglyceridemia, diabetes and hepatic steatosis.

Cilofexor plus firsocostat for 48 weeks was safe and well tolerated in patients with fibrosis due to nonalcoholic steatohepatitis, according to research presented at The Digital International Liver Congress.

Fibroblast growth factor 19 analogue aldafermin showed dose- and duration-dependent reduction in liver fat with resolution of non-alcoholic steatohepatitis in more than one-fifth of cases, according to a presenter at the Digital International Liver Congress.

Machine learning may be a reasonable solution for screening for fatty liver in the general population in areas where more niche noninvasive tests are unavailable, according to a presenter at the Digital International Liver Congress.

Early and sustained improvements in non-invasive markers of nonalcoholic steatohepatitis and advanced fibrosis were observed in patients treated with obeticholic acid, according to research presented at The Digital International Liver Congress.

In this exclusive video, Thomas Berg, MD, head of the section of hepatology at The University of Leipzig, discusses data presented at The Digital International Liver Congress on the role of non-alcoholic fatty liver disease in COVID-19 mortality risk.

Through an international registry presented at the Digital International Liver Congress, experts found COVID-19 in the presence of liver disease like non-alcoholic fatty liver disease or cirrhosis conferred a greater risk for mortality and morbidity.

By 2040, researchers predict 75% of cirrhosis cases in North America will be due to nonalcoholic fatty liver disease with a nearly 350% increase in women born after 1980, according to a presenter at the Digital International Liver Conference.

TVB-2640, a fatty acid synthase inhibitor, significantly reduced liver fat and serum biomarkers of liver injury, fibrosis and inflammation in patients with nonalcoholic steatohepatitis according to research presented at The Digital International Liver Congress.

People who carry a certain genetic variant are at lower risk for developing severe alcoholic hepatitis, according to research presented at The Digital International Liver Congress.